

- Goldstein DP, Berkowitz RS. The diagnosis and management of molar pregnancy. In: Friedman EA, ed. *Gestational Trophoblastic Neoplasms: Clinical Principles of Diagnosis and Management*. Philadelphia: WB Saunders; 1982;143:1–301.
- Hertig AT, Sheldon H. Hydatidiform mole: a pathologic-clinical correlation of 200 cases. *Am J Obstet Gynecol* 1947;53:1–36.
- Fisher RA. Genetics. In: Hancock BW, Newlands ES, Berkowitz RS, eds. *Gestational Trophoblastic Disease*. London: Chapman and Hall; 1997;5:5–26.
- McFadden DE, Kalousek DK. Two different phenotypes of fetuses with chromosome triploidy: correlation with parental origin of the extra haploid set. *Am J Med Genet* 1991;38:535–538.
- Feltmate CM, Growdon WB, Wolfberg AJ, et al. Clinical characteristics of persistent gestational trophoblastic neoplasia after a partial hydatidiform molar pregnancy. *J Reprod Med* 2006;51:902–906.
- Dubeshter B, Berkowitz RS, Goldstein DP, et al. Metastatic gestational trophoblastic disease: experience of the New England Trophoblastic Disease Center 1965–1985. *Obstet Gynecol* 1987;69:390–395.
- Hassadia A, Gillespie A, Tidy J, et al. Placental site trophoblastic tumor: clinical features and management. *Gynecol Oncol* 2005;99:603–607.
- Cole LA, Khanlian SA, Muller CY, et al. Gestational trophoblastic diseases: 3. Human chorionic gonadotropin-free β -subunit, a reliable marker of placental site trophoblastic tumors. *Gynecol Oncol* 2006;102:160–164.
- Shih IM, Kurman RJ. Epithelioid trophoblastic tumor: A neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor. *Am J Surg Pathol* 1998;223:1393–1403.
- Berkowitz RS, Goldstein DP. Clinical practice. Molar pregnancy. *N Engl J Med* 2009;360:1639–1645.
- Kohorn EI. The new FIGO 2000 staging system and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. *Int J Gynaecol Cancer* 2001;11:73–77.
- Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic disease. *Gynecol Oncol* 2009;112:654–662.
- Hancock BW. hCG measurement in gestational trophoblastic neoplasia. A critical appraisal. *J Reprod Med* 2006;51:859–860.
- Cole LA, Butler SA. Hyperglycosylated human chorionic gonadotropin and human chorionic gonadotropin free β -subunit: tumor markers and tumor promoters. *J Reprod Med* 2008;53:499–512.
- Goldstein DP, Aono T, Taymor ML, et al. Radioimmunoassay of serum chorionic gonadotropin activity in normal pregnancy. *Am J Obstet Gynecol* 1968;102:110–114.
- Khanlian SA, Cole LA. Management of gestational trophoblastic disease and other cases with low serum levels of human chorionic gonadotropin. *J Reprod Med* 2006;51:812–818.
- Muller CY, Cole LA. The quagmire of hCG and hCG testing in gynecologic oncology. *Gynecol Oncol* 2009;112:663–672.
- Berkowitz RS, Birnholz J, Goldstein DP, et al. Pelvic ultrasonography and the management of gestational trophoblastic disease. *Gynecol Oncol* 1983;15:403–412.
- Garner EI, Garrett A, Goldstein DP, et al. Significance of chest computed tomography findings in the evaluation and treatment of persistent gestational trophoblastic neoplasms. *J Reprod Med* 2004;49:411–414.
- Athanassiou A, Begent RH, Newlands ES, et al. Central nervous system metastases of choriocarcinoma: 23 years' experience at Charing Cross Hospital. *Cancer* 1983;52:1728–1735.
- Bagshawe KD, Harland S. Immunodiagnosis and monitoring of gonadotropin-producing metastases in the central nervous system. *Cancer* 1976;38:112–118.
- Bakri YN, Al-Hawashim N, Berkowitz RS. Cerebrospinal fluid/serum beta-subunit human chorionic gonadotropin ratio in patients with brain metastases of gestational trophoblastic tumor. *J Reprod Med* 2000;45:94–96.
- Dhillon T, Palmieri C, Sebire NJ, et al. Value of whole body 18 FDG-PET to identify the active site of gestational trophoblastic neoplasia. *J Reprod Med* 2006;51:879–887.
- Mapelli P, Mangili G, Picchio M, et al. Role of 18F-FDG-PET in the management of gestational trophoblastic disease. *Eur J Nucl Med Mol Imaging* 2013;40:505–513.
- Kohorn EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia: a progress report. *J Reprod Med* 2002;47:445–450.
- Committee on Practice Bulletins-Gynecology, American College of Obstetricians and Gynecologists. ACOG Practice Bulletin #53. Diagnosis and treatment of gestational trophoblastic neoplasms. *Obstet Gynecol* 2004;103:1365–1377.
- McGrath S, Short D, Harvey R, et al. The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100,000 IU/L. *Brit J Cancer* 2010;102:810–814.
- Osborne RJ, Filiaci V, Schink JC, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. *J Clin Oncol* 2011;29:825–831.
- Hoekstra AV, Lurain JR, Rademaker AW, et al. Gestational trophoblastic neoplasia: treatment and outcomes. *Obstet Gynecol* 2008;112:251–258.
- Agahjani C. Treatment of low-risk gestational trophoblastic neoplasia. *J Clin Oncol* 2011;29:786–788.
- Lurain JR, Chapman-Davis E, Hoekstra AV, et al. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia. *J Reprod Med* 2012;57:283–287.
- Maesta I, Growdon WB, Goldstein DP, et al. Prognostic factors associated with time to hCG remission in patients with low-risk post-molar gestational trophoblastic neoplasia. *Gynecol Oncol* 2013;130:312–316.
- Chapman-Davis E, Hoekstra AV, Rademaker AW, et al. Treatment of non-metastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single agent methotrexate chemotherapy. *Gynecol Oncol* 2012;125:572–575.
- Shah NT, Barroilhet L, Berkowitz RS, et al. A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia. *J Reprod Med* 2012;57:211–218.
- Berkowitz RS, Goldstein DP. Chorionic tumors. *N Engl J Med* 1996;335:1740–1748.
- Lybol C, Sweep FC, Harvey R, et al. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. *Gynecol Oncol* 2012;125:576–579.
- Berkowitz RS, Goldstein DP, Bernstein MR. Modified triple chemotherapy in the management of high-risk metastatic gestational trophoblastic tumors. *Gynecol Oncol* 1984;19:173–181.
- Clark RM, Nevadunsky N, Ghosh S, et al. The evolving role of hysterectomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. *J Reprod Med* 2010;55:194–198.
- Cole LA, Khanlian A, Muller CY. Normal production of human chorionic gonadotropin in menopause. *N Engl J Med* 2007;356:1184–1186.
- Lurain JR, Schink JC. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. *J Reprod Med* 2012;57:219–224.
- Gagayan MS. High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMAC-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy. *J Reprod Med* 2012;57:231–236.
- Xiang Y, Sun Z, Wan X, et al. EMA/EP chemotherapy for chemorefractory gestational trophoblastic tumors. *J Reprod Med* 2004;49:443–446.
- Alazzam M, Tidy J, Osborne J, et al. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. *Cochrane Database Syst Rev* 2012;12:CD008891.
- Zhao Y, Zhang W, Duan W. Management of gestational trophoblastic neoplasia with 5-fluorouracil and actinomycin D in northern China. *J Reprod Med* 2009;54:88–94.
- Alifrangis C, Agarwal R, Short D, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: Good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. *J Clin Oncol* 2012;31:280–286.
- Lurain JR. Gestational trophoblastic disease. II. Classification and management of gestational trophoblastic neoplasia. *Am J Obstet Gynecol* 2011;204:11–18.
- Brace KC. The role of irradiation in the treatment of metastatic trophoblastic disease. *Radiology* 1968;91:540–544.
- Newlands ES, Holden L, Seckl MJ, et al. Management of brain metastases in patients with high risk gestational trophoblastic tumors. *J Reprod Med* 2002;47:465–471.
- Lurain JR, Singh DK, Schink JC. Role of surgery in the management of high-risk gestational trophoblastic neoplasia. *J Reprod Med* 2006;51:773–776.
- Fleming EI, Garrett LA, Growdon WB, et al. The changing role of thoracotomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. *J Reprod Med* 2008;53:493–498.
- Alifrangis C, Wilkinson MJ, Stefanou DC, et al. Role of thoracotomy and metastatectomy in gestational trophoblastic neoplasia. A single center experience. *J Reprod Med* 2012;57:350–358.
- Neubauer NL, Latif N, Kalakota K, et al. Brain metastasis in gestational trophoblastic neoplasia. An update. *J Reprod Med* 2012;57:288–292.
- Feltmate CM, Genest DR, Goldstein DP, et al. Advances in the understanding of placental site trophoblastic tumor. *J Reprod Med* 2002;47:337–341.
- Kingdon SJ, Coleman RE, Ellis L, et al. Deaths from gestational trophoblastic neoplasia. Any Lessons to be learned? *J Reprod Med* 2012;57:293–296.
- Hyman DM, Bakios L, Gualtiere G, et al. Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome. *Gynecol Oncol* 2013;129:58–62.
- Garrett LA, Garner EIO, Feltmate CM, et al. Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia. *J Reprod Med* 2008;53:481–486.
- Wenzel LB, Berkowitz RS, Habbal R, et al. Predictors of quality of life among long-term survivors of gestational trophoblastic disease. *J Reprod Med* 2004;49:589–594.